Dr Bob Taylor
Contact information
Research groups
Bob Taylor
Senior Clinical Research Fellow
Vivax malaria
Dr Bob Taylor works on drug trials for vivax and falciparum malaria. In contrast with falciparum malaria, vivax malaria can relapse from dormant stage parasites in the patient’s liver. Primaquine is currently the only available drug to prevent relapse infections but can cause severe haemolysis in patients with reduced G6PD activity. Dr Taylor's research aims to determine the most effective and safest way to radically cure vivax malaria.
Podcast interview
Primaquine for vivax and falciparum malaria
Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.
Recent publications
-
Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
Hamaluba M. et al, (2021), The Lancet. Infectious diseases
-
Phylogenetic analysis of Trichostrongylus vitrinus isolates from southwest Iran.
Ghatee MA. et al, (2020), Parasites & vectors, 13
-
Environmental, climatic and host population risk factors of human cystic echinococcosis in southwest of Iran.
Ghatee MA. et al, (2020), BMC public health, 20
-
Primaquine for Plasmodium vivax malaria treatment – Authors' reply
Price RN. et al, (2020), The Lancet, 395, 1972 - 1972
-
Urinary balantidiasis in a patient with systemic lupus erythematosus and lupus nephritis: a case report.
Martviset P. et al, (2020), Journal of medical case reports, 14